kdalfaro

In this session, Dr Sam Klempner from Massachusetts General Hospital discusses the use of circulating tumor DNA (ctDNA) testing to monitor for minimal residual disease (MRD) in GI cancer. https://youtu.be/HSMwPqhGVxo?si=_z2RUr2gkXmAT8Hj

In this presentation, the Dr. John Stricker discusses the use of circulating tumor DNA (ctDNA) testing in colorectal cancer patients to guide treatment decisions. The presentation includes discussions on the sensitivity and specificity of ctDNA testing and its potential impact on treatment strategies. Several case studies are presented, highlighting the challenges and considerations when interpreting ctDNA results, especially in the context of adjuvant chemotherapy decisions for stage two colorectal cancer patients. The speaker emphasizes the need for careful evaluation and monitoring of ctDNA status to make informed treatment choices and discusses ongoing research in this area. https://youtu.be/b4qaM-Iqie0?si=RQGWPGvyxGr0dmHw [...]

Afsaneh Barzi, MD, PhD, City of Hope, Duarte, CA, provides an overview of the clinical impact of minimal residual disease (MRD) testing in colorectal cancer, and strategies to optimize sensitivity. False negatives may occur during testing, and there is no definite treatment regimen for patients who are MRD positive post-surgery. MRD testing alone should additionally not determine whether patients should receive adjuvant therapy. Dr Barzi also highlights disparities in the use of MRD testing. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA. These works are owned by [...]

Dr. Y. Nancy You shares what young adults should know about colon cancer. https://youtu.be/Vb8R1bCtCDw?si=nK7kwb9AhAC8Fumf

Benny Johnson, DO, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses strategies to enhance the efficacy of immunotherapies in microsatellite stable (MSS) colorectal cancer, a subtype that is typically immunologically cold. Targeting pathways such as VEGF and developing TKIs may provide a path for immunotherapies to be efficacious. Cellular therapies such as CAR-T cell therapies and neoantigen vaccines with checkpoint inhibition additionally represent promising strategies on the horizon. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL. These works are owned by Magdalen Medical Publishing (MMP) and are [...]

Dr. Kanwal Raghav provides an overview of upcoming clinical trial, RX-CROME, for high-risk patients with Colorectal Cancer with radiographic occult molecular residual disease. .  For Phase 1 discussion of XmAB20717: Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors: https://jitc.bmj.com/content/9/Suppl_2/A553 NCI information of XMAB20717:  https://www.mycancergenome.org/content/drugs/xmab20717/